Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post COVID Syndrome’

Neobiosis, A UF Accelerate resident client, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of 'Post COVID Syndrome (AKA "Long Haul COVID Syndrome").

Lacerta and Prevail, a Wholly Owned Subsidiary of Lilly, Sign Agreement To Develop Novel AAV Capsids for CNS Disorders

Lacerta Therapeutics, a leader in the development of adeno-associated virus (AAV) technologies for the treatment of central nervous system (CNS) diseases, announced a new AAV capsid licensing and research collaboration agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. The collaboration will focus on the discovery and development of novel AAV capsids for CNS diseases.

Admiral Named One of the Fastest Growing Companies in U.S.

The UF Innovate | Accelerate resident client Admiral also ranked as Top 100 (75) of Marketing and Advertising companies, Top 100 (90) from the state of Florida, and the #1 fastest growing company from its hometown of Gainesville, FL

Rain Neuromorphics Tapes Out Demo Chip for Analog AI

UF startup and UF Innovate | Accelerate graduate Rain Neuromorphics, which incubated at The Hub, has taped out a demonstration chip for its brain-inspired analog architecture that employs a 3D array of randomly-connected memristors to compute neural network training and inference at extremely low power.